Berlin-based medical AI company Ada Health has announced the launch of a new partnership with Novartis in order to speed up the diagnosis for patients with immunological diseases and rare conditions.
The partnership will see Novartis use Ada Health’s AI-based, clinically validated, symptom assessment and care navigation solutions to help improve the identification and diagnosis of a number of diseases.
WHY IT MATTERS
One of the conditions that Ada and Novartis are focused on is axial spondyloarthritis (axSpA), along with psoriatic arthritis (PsA) and familial Mediterranean fever (FMF).
Axial Spondyloarthritis is a chronic inflammatory disease that can lead to chronic pain, structural damage and disability. Affecting around one in 200 adults, axSpA is notoriously difficult to identify. Timely diagnosis is a critical factor for a patient’s future quality of life but symptoms can present in many ways and be indicative of other conditions. Worldwide, the delay to diagnosis averages about five years – with women taking two years longer than men to be diagnosed.
To address this challenge, celexa class of antidepressant the Ada Health team has developed and optimised computerised disease models that aid differentiation of the signs and symptoms of conditions that may appear similar in nature. At the end of an assessment, users are offered a number of options to help them take the next steps. Options include learning more about axSpA, booking an appointment with a doctor or finding a specialist located near to them.
London's Royal Free Hospital to use AI keyhole procedure for heart attack patients
Caretech company Birdie raises £8.2M for elderly health and care
British health tech firm Huma secures $130 million in Series C round
Source: Read Full Article